Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis

INTRODUCTION: This randomized, double-blind, phase II study evaluated the pharmacodynamics, safety and tolerability of ISIS 329993 (ISIS-CRP(Rx)), an antisense oligonucleotide, in patients with active rheumatoid arthritis (RA). METHODS: Patients with active RA of at least six months duration were ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Warren, Marshelle S, Hughes, Steven G, Singleton, Walter, Yamashita, Mason, Genovese, Mark C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415222/
https://www.ncbi.nlm.nih.gov/pubmed/25885521
http://dx.doi.org/10.1186/s13075-015-0578-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415222/
https://www.ncbi.nlm.nih.gov/pubmed/25885521
http://dx.doi.org/10.1186/s13075-015-0578-5

Ejemplares similares